Omalizumab Reduces Asthma Exacerbations Across Airway Reversibility Subgroups
Treatment with omalizumab may reduce exacerbations of asthma in patients in several different airway reversibility subgroups.
In-Depth Focus From ACAAI 2019: Asthma
Worsening of Disease Common in Asthma Prior to Biologic Therapy Initiation
Patients who began biologic treatment for asthma tended to have more progressive worsening of disease in the previous 2 years
Benralizumab Does Not Cause Changes in Weight, Blood Pressure in Severe Asthma
Benralizumab does not induce changes in weight or blood pressure when administered for up to 1 year in patients with severe asthma.
Mometasone Furoate-Formoterol Improves Lung Function in Pediatric Asthma
The addition of formoterol to mometasone furoate was well tolerated and provided significant improvement in lung function in children compared with mometasone furoate alone.
Benralizumab Associated With Improvements in SGRQ Scores in Asthma
In patients with asthma, benralizumab is associated with substantial improvements in total scores on the St. George’s Respiratory Questionnaire.
Omalizumab Response Similar Across Number, Type of Allergens in Allergic Asthma
Response to omalizumab was similar regardless of the number and type of sensitizing allergens in patients with allergic asthma.
Want to read more?
Please login or register first to view this content.
Next post in ACAAI 2019 In-Depth Asthma
